WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants
Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...
Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...
China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
The National Vaccine & Serum Institute has announced a partnership with Corning Life Sciences, aiming...
The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on...
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Novasight Hybrid System, a...
China-based HitGen Inc. (SHA: 688222) has announced a research agreement with ARase Therapeutics, Inc. Under...
China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max...
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving clinical trial approval from the...
Everest Medicines (HKG: 1952), a China-based biopharmaceutical company, has declared the successful completion of patient...
HuidaGene Therapeutics, a China-based biotechnology company, has announced the receipt of patent protection from the...
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced the receipt of...
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its tetravalent influenza virus split vaccine,...
The Center for Drug Evaluation (CDE) website in China indicates that AstraZeneca’s (AZ, NASDAQ: AZN)...
Antengene Corp., Ltd (HKG: 6996) has announced a market approval filing in Indonesia for its...
Shanghai-based TYK Medicines has announced that it has received approval from the Center for Drug...
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor,...
Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...